Editorial comment.
Shepard
Dale R
DR
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D003430:Cross-Sectional Studies; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D009919:Orchiectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000628:therapy*; D014105:Tosyl Compounds / Q000009:adverse effects / Q000627:therapeutic use
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; D007987:Gonadotropin-Releasing Hormone; C053541:bicalutamide